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Clinically and pathologically, the patients with hyper-IgE syndrome present similar skin manifestations
to common atopic dermatitis. The original hyper-IgE syndrome is characterized by diminished inflam-
matory response, in combination with Staphylococcus aureus skin abscess and pneumonia followed by
pneumatocele formation. These immunological manifestations are frequently associated with skeletal
and connective tissue abnormalities. We previously identified that major causal variants of the hyper-IgE
syndrome are dominant negative variants in the STAT3.
In addition to the identification of new causative variants for the disorders similar to the original
hyper-IgE syndrome, causative variants for new types of hyper-IgE syndrome centered only on atopy,
high serum IgE levels, and susceptibility to infection, but not associated with diminished inflammatory
response, pneumatocele formation, and connective tissue manifestations, have been identified. Recent
discovery identified a novel zinc finger protein that regulates STAT3 transcription. Investigation of IL6ST
variants disclosed that IL6ST/IL6R cytokine receptor plays a crucial role for the signal transduction up-
stream of STAT3 in the pathogenesis of the original hyper-IgE syndrome. Even if the same IL6ST variants
are used for the signal transduction of IL-6 family cytokines, the signaling defect is more severe in IL-6/IL-
11 and milder in LIF. The fact that the non-immune manifestations of the gain-of-function mutations of
TGFBR1 and TGFBR2 are similar to the those of dominant negative mutations of STAT3 provide a clue to
elucidate molecular mechanisms of non-immune manifestations of hyper-IgE syndrome. Research on
this hereditary atopic syndrome is being actively conducted to elucidate the molecular mechanisms and
to develop new therapeutic approaches.
Copyright © 2021, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hyper-IgE syndrome (HIES) is first described by Davis and
Wedgwood in 1966, in two girls suffering from recurrent cold
staphylococcal abscesses, pneumonia, and neonatal-onset eczema.1
As this original report predated the identification of IgE,2 a high
serum concentration of IgE level was not recognized at this point.
This syndrome was further characterized by Buckley et al.,3 who
found that recurrent staphylococcal abscesses and chronic eczema
were associated with exceptionally high serum concentrations of
IgE. They also showed that serum concentrations of the other im-
munoglobulins (IgG, IgA, IgM, and IgD) and IgG subclasses were
normal in the patients. The non-immunological manifestations of
HIES were established by Grimbacher, to extend to skeletal and
connective tissue abnormalities, such as scoliosis, osteoporosis,
fracture following minor trauma, hyper-extensive joints, and the
retention of deciduous teeth.4 In 2004, autosomal recessive (AR).ac.jp.
ety of Allergology.
rgology. Production and hosting by Elseform of HIES was reported in consanguineous families,5 most of
which is caused by the loss-of-function (LOF) mutations in the
Dedicator of cytokinesis 8 (DOCK8) gene.6 In 2007, dominant-
negative (DN) mutations in the signal transducer and activator of
transcription 3 (STAT3) gene were identified as a major molecular
etiology of classical HIES.7 There are several review articles dis-
cussing this type of HIES.8e11 Recently, it is postulated that HIES
could include all the disorders presenting the three manifestations,
i.e. atopic dermatitis, high serum IgE levels, and susceptibility to
infections, in contrast to the narrow definition of the original
STAT3-DN HIES.
At present, it is difficult to provide a definition of HIES that
everyone is satisfied with. Based on the recent International Union
of Immunological Societies (IUIS) PID classification 12,13 and Online
Mendelian Inheritance in Man (OMIM) (https://www.ncbi.nlm.nih.
gov/omim), I selected nine causative genes-function of mutations
of the HIES, on the condition that at least two patients from two
independent families were identified, i.e. (1) STAT3-DN, (2) Zinc
Finger Protein 341 (ZNF341)-LOF, (3) Interleukin 6 Signal Trans-
ducer (IL6ST)-partial LOF, (4) IL6ST-DN, (5) IL6R-LOF, (6) Tyrosinevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Y. Minegishi / Allergology International 70 (2021) 407e414408kinase 2 (TYK2)-LOF, (7) Serine Peptidase Inhibitor Kazal Type 5
(SPINK5)-LOF, (8) Transforming Growth Factor Beta Receptor
(TGFBR) 1/2-GOF, (9) Caspase recruitment domain-containing
protein 11 (CARD11)-DN. This has more information compared to
classical autosomal dominant (AD) and AR classification, and easier
to understand for non-specialists of PIDs. Because most of the pa-
tients with phosphoglucomutase 3 (PGM3)-partial LOF displayed
impaired T-cell proliferation in response to PHA, anti-CD3, purified
protein derivative (PPD), or tetanus toxoid (TT),14,15 I classified this
disorders into combined immunodeficiency (CID) category and will
not discuss in this article.STAT3-DN
STAT3 is a transcription factor that binds to the STAT3-
responsive elements in the promoters of various genes, including
acute-phase reaction proteins (Fig. 1).16,17 STAT3 plays a critical role
in responses to many cytokines and growth factors, including gc
cytokines (IL-2, IL-7, IL-9, IL-15, and IL-21), GP130 cytokines (IL-6,
IL-11, IL-27, IL-35, IL-39, cardiotrophin-1 (CT-1), cardiotrophin-like
cytokine factor 1 (CLCF1), oncostatin M (OSM), and leukemia
inhibitory factor (LIF), ciliary neurotrophic factor (CNTF)), type 1
and type 2 IFNs (IFNa, IFNb, and IFNg), IL-10 family cytokines (IL-10,
IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29), receptor tyrosine
kinases (epidermal growth factor (EGF), fibroblast growth factor
(FGF), fms like tyrosine kinase 3 (Flt3) ligand, growth hormone
(GH), insulin-like growth factor 1 (IGF1), macrophage colony-
stimulating factor (M-CSF), and platelet-derived growth factor
(PDGF), as well as IL-5, IL-12, IL-23, granulocyte-colony stimulating
factor (G-CSF), leptin, and platelet activating factor (PAF). A null
mutation in the STAT3 gene in mice demonstrated that STAT3 was
essential for the survival of the embryo around the time of im-
plantation.18 The mice with tissue-specific deletions of STAT3 have
shown STAT3 to play a crucial role in cell proliferation, survival,
migration, apoptosis and inflammation in various tissues, organs
and cells, including skin, respiratory epithelium, thymic epithelium,
liver, mammary glands, neurons, lymphocytes, and macrophages.19Fig. 1. Signal transduction of IL6-IL6R-IL6ST. IL6 binds to IL6R with low affinity, which is not
Soluble IL6R can be produced by alternative splicing or proteolytic cleavage, which can also
then JAKs phosphorylate tyrosine residues in the cytoplasmic domain of GP130, leading t
dimerize and translocated into the nucleus to the IL6-responsive elements identified in th
mutations of the IL6R, IL6ST, and STAT3 genes.It is considered that many of the clinical signs of STAT3-DN HIES
likely reflect defects of the diverse functions of STAT3 in vivo.
Most of the patients with STAT3-DN HIES suffer from recurrent
staphylococcal infections, beginning in infancy and predominantly
involving the skin and lungs. Staphylococcus aureus is the bacterium
most frequently isolated from the patients, but Streptococcus
pneumoniae, Haemophilus influenzae, and enteric Gram-negative
bacteria are occasionally isolated from the patients. Fungal in-
fections, including mucocutaneous candidiasis and pulmonary
aspergillosis, are also common in STAT3-DN HIES. Eczema usually
begins during the neonatal period, earlier than the onset of com-
mon atopic dermatitis. Patients with HIES are usually free from
other allergic manifestations, such as allergic rhinitis, asthma, food
allergy, and anaphylaxis.
STAT3-DN HIES is associated with non-immunological mani-
festations, including characteristic facial appearance, pneumato-
cele formation, fracture due to minor external force (pathological
fracture), osteoporosis, scoliosis, joint hyperextension, delayed loss
of deciduous tooth. There is an increased rate of malignancy, pre-
dominantly malignant lymphoma. In most STAT3-DN HIES, the
serum IgE levels are elevated, frequently higher than 2000 IU/ml.
However, there are cases with only mildly elevated IgE and the IgE
can fall into the normal range. Specific IgE against S. aureus and
Candida albicans is elevated, and it is thus considered that antigen-
specific IgE production is enhanced in this disorder. Eosinophilia is
present in about 90% of the patients, and the number of eosinophils
in the peripheral blood was mostly higher than 700/ml.
The other immunoglobulins levels are generally normal, and
antibody responses to vaccination are impaired at least some of the
HIES patients.20,21
STAT3 mutations are localized mostly to the DNA binding, SH2,
and transactivation domain (Fig. 2). Mutations are in most part
missense mutations and some small in-frame deletions. So far, there
is no convincing report that STAT3 haploinsufficiency can cause this
syndrome. STAT3 protein is present and can dimerize with wild type
STAT3 protein, but inhibit STAT3 signaling of wild-type allele, i.e.
function as dominant negative. The number of Th17 cells and
memory B cells in peripheral blood is decreased. STAT3 signalsufficient for signal transduction. IL6-IL6R complex binds to IL6ST to initiate signaling.
initiate signaling. Hexameric IL6-IL6R-IL6ST complex induces phosphorylation of JAKs,
o the recruitment and activation of STAT1, STAT3, and, STAT5. Phosphorylated STATs
e promoters of various acute-phase protein genes. IL-6 signaling is disrupted by the
Fig. 2. Structure and mutations of STAT3. Structure and mutations of STAT3 is shown. Most of the mutations are located in the DNA binding, SH2, and transactivation domain. There
are three hot spots for the mutations, i.e. R382, V463, and V637, shown with red arrows. Approximately 60% of the mutations are located in the hot spots.
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elevated acute phase protein such as C reactive protein (CRP).
Therefore, it is desirable to use an earlier marker such as IL-6 as a
severity marker in the early stage of infection. In addition, when a
child suffers from an early stages of severe infection, it is charac-
teristic that the feeling of seriousness is lacking. Thus, it is necessary
to pay close attentionwhenyou follow up this HIES patients, and it is
recommended that the patients to be followed by PID specialists.
If suspected with newborn rash in combination with S. aureus
infections and high serum IgE levels, in theory, we could diagnosis
STAT3-DN HIES in newborn period. Early definitive diagnosis and
start of prophylaxis might be able to prevent pneumatocele for-
mation to improve quality of life of the HIES patient. But in practice,
because of the rarity of this syndrome, it is difficult to diagnose this
disorder in the neonatal period. Prophylactic antibiotics and anti-
fungals are given in most cases of STAT3-DN HIES.22,23 As an anti-
bacterial agent against S. aureus, trimethoprim/sulfamethoxazole is
generally used. It is relatively difficult to be resistance to the drug
evenwhen used for a long period of time. In addition, penicillinase-
resistant penicillin antibiotic flucloxacillin and macrolide azi-
thromycin may be administered. Since S. aureus is resident on the
skin at a high rate, reduction of the amount of S. aureus by a bleach
bath may improve atopic dermatitis. Prophylactic administration of
anti-fungal agents such as itraconazole, voriconazole, and pos-
aconazole, which are sensitive to Aspergillus, is also recommended.
Long term use of these drug is associated with adverse effects.24
Periodical blood chemistry and careful monitoring of drug serum
levels are a critical component of this prophylaxis. In some patients
with STAT3-DN HIES, surgical removal of the pneumatocele may be
considered, but the frequency of complications is high, and it is
necessary to carefully consider the surgical indication.23 Immuno-
globulin replacement therapy is recommended for children with
this disease because of the deficiency in the production of specific
antibodies.
As a curative treatment, hematopoietic stem cell transplantation
(HSCT) has not been performed much because of the symptoms of
non-hematopoietic tissues in STAT3-DN HIES, but impaired differ-
entiation of Th17 cells is involved in the development of bacterial
and fungal infections. Therefore, hematopoietic stem cell trans-
plantation is being considered in cases where it is difficult to con-
trol lung infections with antibiotics. Application of HSCT to STAT3-
DN HIES is still controversial and future studies are needed. Organic
changes in the lungs (bronchiectasis and pneumatocele) are
important factors in the prognosis of the patients, and regular
follow-ups including chest computed tomography (CT) are rec-
ommended. Vaccination, including live vaccines, are well tolerated,
with the exception of the pneumococcal polysaccharide vaccine,
which might induce severe necrotic reactions.25Fig. 3. Structure and mutations of ZNF341. Structure and mutations of ZNF341 is
shown. Each shaded box indicates zinc finger (ZF) domain. Nuclear localization signal
(NLS) is located in ZF2-ZF3 and ZF10-ZF11. LOF mutations in the ZNF341 are shown in
red.ZNF341-LOF
Homozygous mutations in the ZNF341 gene were reported in 19
patients from 10 families as a new type of HIES.26,27 Most of thepatients are middle east origin and clinically similar to STAT3-DN
HIES patients, suffering from eczema, mucocutaneous candidiasis,
and elevated serum IgE levels. The patients, however, showed
stronger inflammatory responses and fewer non-immunological
manifestations compared to STAT3-DN HIES. ZNF341 is a previ-
ously unexplored putative transcription factor containing 12C2H2
zinc finger (ZF) domains (Fig. 3). The mutations in ZNF341 are ho-
mozygous nonsense or frameshift mutations that induce truncation
of the ZNF341 protein, but interestingly, nonsense mediated mRNA
decay does not operate in this gene and truncated ZNF341 protein
can be expressed at least some of the patients. ZNF341 proteins do
not interact with wild-type ZNF341 even after stimulation, and two
of the mutant proteins (Q195X and R302X) are retained in the
cytoplasm, suggesting these mutants are complete LOF. Chromatin
immunoprecipitation-sequencing (ChIP-seq) analysis with the
anti-ZNF341 mAb identified that strongest ZNF341-binding site
was located in the STAT3 promoter region and strong ZNF341
binding was also observed in the STAT1 promoter and ZNF341
intron 1. There are two isoforms in ZNF341 protein, both isoforms
induced expression from the STAT1 and STAT3 promoters by re-
porter assays. Three of the five mutants induced no luciferase ac-
tivity, confirming that the Q195X, R302X and K355fs mutant alleles
were complete LOF. By contrast, the Y542X mutant, which can bind
to the canonical motif on Electrophoresis Mobility Shift Assay
(EMSA) and in pulldown assay. The mutant yielded intermediate
levels of luciferase activity, suggesting that it is partial LOF, at least
when overexpressed.
The patients had decreased Th17 cells, and lower central
memory CD4þ and CD8þ T cells, higher proportions of naive CD4þ
T cells, but had normal proportions of Treg cells, gd T cells, and
invariant NKT cells. The lymphocyte subset of ZNF341-LOF closely
resembles that of STAT3-DN HIES. However, by closely looking at
the cellular phenotype of the ZNF341 deficiency, the pathogenesis
of this HIES might be more complex than originally conceived.
Immortalized cell lines, including EBV-LCL, SV40 transformed fi-
broblasts, and Herpesvirus saimiri (HVS) immortalized T cell lines,
from the patients displayed no major STAT3-DN phenotype.
Furthermore, ZNF341 deficient monocytes are not functionally
impaired in STAT3 signaling, although the expression levels of
STAT3 is lower compared to wild-type ZNF341. Interestingly, STAT3
activity is impaired in ZNF341-deficient B cells and STAT3 auto-
induction is impaired in ZNF341-deficient naïve CD4þ T cells,
Fig. 4. Structure and mutations of IL6ST/GP130 and IL6R. The IL-6 receptor complex is
composed of two different subunits, IL-6 binding subunit, IL-6R, and signal transducing
subunit IL6ST/GP130. Both IL6ST/GP130 and IL6R are a single-pass transmembrane
protein. LOF mutations in the IL6ST/GP130 are located in the extracellular domain, and
DN mutations are located in the cytoplasmic region between JAK binding Box1/Box2
and STAT3 binding tyrosine residue 767. LOF mutations in the IL6R are located in the
extracellular region.
Y. Minegishi / Allergology International 70 (2021) 407e414410therefore Th17 cell development is impaired in ZNF341-deficient
naive CD4 T cells.
It is hypothesized that ZNF341 is a positive regulator of STAT3
expression and homozygous nonsense mutations in ZNF341 lead to
insufficient STAT3 expression, which is likely to cause HIES phe-
notypes. Because no STAT3-DN HIES caused by haploinsufficiency
has been reported in the human STAT3 loci, it is conceived that in
order to develop HIES manifestations, STAT3 activity needs to be
lower than 50%. The authors showed that ZNF341 deficiency leads
to a 50% decrease in expression levels of STAT3 and a >60% decrease
in phosphorylation levels of STAT3 upon stimulation with STAT3-
activating cytokines in T cells. Clearly, more work is needed to
understand the exact role of ZNF341 in the pathogenesis of
ZNF341-LOF HIES, since there is no clear demonstration of intro-
duction of wild-type ZNF341 rescue STAT3 expression and
signaling, and there is a possibility that STAT3-independent func-
tion of ZNF341 might also contribute to the phenotype.
IL6ST-partial LOF
IL-6 is considered to be one of the most powerful pro-
inflammatory cytokines. Blockade of IL-6 by the neutralizing anti-
body, tocilizumab, is effective for the treatment for autoimmune
disorders including rheumatoid arthritis. The blockade is also
effective for the cytokine storm due to COVID-19 infection and
chimeric antigen receptor (CAR) T-cell therapy.28
IL6ST encodes GP130 protein, a signaling subunit of IL-6 family
cytokines. IL-6 family cytokines have pleiotropic functions in the
regulation of the acute phase reaction, B-cell stimulation, the
regulation of the balance between regulatory and effector T cells.
The proximal cytoplasmic region of GP130 contains two boxes that
constitutively bind to Janus kinase (JAK) family tyrosine kinases
(Fig. 1). Upon IL-6 binding, JAKs phosphorylate tyrosine residues in
the cytoplasmic domain, Y767, Y814, Y905, Y915, leading to the
recruitment and activation of STAT1, STAT3, and, STAT5. In mice,
complete GP130 deficiency is embryonic lethal29 and in human
complete LOF of IL6ST results in lethal Stüve-Wiedemann syn-
drome, characterized by skeletal dysplasia, neonatal lung
dysfunction, congenital thrombocytopenia, atopic dermatitis, renal
abnormalities, and defective acute-phase response.30
Two patients, South Asian and Turkish descent,31 with homo-
zygous missense mutations in IL6ST, N404Y and P498L, were re-
ported (Fig. 4).32 Signaling defects are partial by evaluating the
reconstituted IL-6 family cytokine receptors in GP130 deficient HEK
293 cells. Signaling is more severely impaired in IL-6, IL-11, IL-27,
and OSM but mildly impaired in LIF signaling. Patient-derived fi-
broblasts showed a substantially reduced STAT3 response to IL-6/
IL-11 stimulation. The defect was rescued by the expression of
wild-type GP130. The patients present with recurrent lung in-
fections, eczema, eosinophilia, high serum IgE levels, impaired
acute-phase responses, craniosynostosis, scoliosis, and deciduous
tooth retention. These findings suggest that IL6ST is the major
upstream cytokine receptor in the pathogenesis of STAT3-DN HIES.
IL6ST-DN
Dominant negative heterozygous mutations in IL6ST were
identified in 12 patients from eight unrelated families (Fig. 4).33
These patients have very similar clinical phenotype with STAT3-
DN HIES including pneumatocele. Non-immunological features
such as scoliosis, osteoporosis, retention of primary teeth were also
present in the IL6ST-DN HIES. Interestingly, however, unlike the
patients with STAT3-DN, IL6ST-partial LOF, or complete IL11RA
deficiency, patients with IL6ST-DN do not present craniosynostosis,
presumably due to residual activity in IL-11 signaling.34All 10 patients had a heterozygous stop codon or frameshift
mutation in IL6ST. The segregation patterns of the mutants were
consistent with an autosomal dominant inheritance with full
penetrance like STAT3-DN HIES. The mutations, (c.2121del;
p.L708X), (c.2155dup; p. I719Nfs), (c.2277T > G; p.Y759X), and
c.2224dup; p.742Ffs) had occurred de novo. All the IL6ST variants
clustered in the intracellular region between Box1/Box2 (651e700
Aa) and tyrosine 767 (Fig. 4). Box1 proline motif interact with 4.1
protein, ezrin, radixin and moesin (FERM) domain and Box2 hy-
drophobic motif interacts with SH2 domain of JAK family kinases.
All the mutated alleles encode receptors that could stably reach to
the cell surface, due to the truncation of the recycling motif
(783e792 Aa). The accumulation of the mutations in the patients
suggests this character is required to be a dominant negative GP130
receptor. Again, STAT3 can transmit a signal in many non-GP130
associated receptors, but the similar phenotype between STAT3-
DN and IL6ST-DN HIES strongly suggest that signaling defects of
IL6ST dependent cytokines are the major players in the pathogen-
esis of STAT3-DN HIES. Patients with IL6ST-DN lack the character-
istic features of Stüve-Wiedemann syndrome,30 reflecting the
presence of residual LIF signaling.IL6R-LOF
Bi-allelic mutations in IL6R, which encodes a ligand binding
subunit, was reported in two unrelated patients, one English and
the other Pakistani origin, with atopic dermatitis, elevated IgE,
reduced inflammatory responses, and recurrent skin and lung in-
fections (Fig. 4).35 The patients suffered from recurrent upper and
lower respiratory tract infections, S. aureus recurrent skin ab-
scesses, CRP was barely above the detection limit during acute
Y. Minegishi / Allergology International 70 (2021) 407e414 411infection. No viral or fungal infections were reported. Serum IgG,
IgA, and IgM levels weremildly reduced and IgE levels was elevated
in both patients, but in one patient the increase was very modest
for HIES; 787 kU/liter (normal range 0e100 kU/liter).
One mutation in the patients was a homozygous frameshift,
G183Efs, and the other was a homozygous missense, I279N,
causing normal protein expression, but impaired function. Neither
was found in the genome Aggregation Database (gnomAD). Pa-
tient T cells showed impaired IL6-mediated phosphorylation of
STAT3 and STAT1, which was restored by the introduction of wild-
type IL6R. The patients had an increased proportion of Forkhead
box P3 (FOXP3) þ regulatory T cells, with increased expression of
FOXP3 protein.
Based on these findings, it is hypothesized that the disruption of
cellular responses to IL-6 alone can underlie most of the features of
the original HIES.36 Although this is a fascinating hypothesis due to
its simplicity, but negative data against this hypothesis is that pa-
tients having neutralizing autoantibodies against IL-6 present with
the similar symptoms as IL-6R LOF with respect to reduced in-
flammatory response but not with atopic manifestations. More
studies are need, especially to identify a molecular mechanism how
IL-6 and/or other signaling molecules regulate atopic manifesta-
tions in STAT3-DN HIES and related disorders.TYK2-LOF
TYK2 is a member of the Janus kinase family (JAK1, JAK2, JAK3,
and TYK2) that plays a crucial role in the signaling of subset of
cytokine receptors including. IFN-a/b, IL-10, IL-12, and IL-23.
Binding of the ligand to these cytokine receptor induces confor-
mational changes and activation of the JAKs kinases via phos-
phorylation. The JAKs phosphorylate the intracellular part of the
receptor which create a docking site for the STATs. STATs are sub-
sequently phosphorylated and translocated to the nucleus to acti-
vate the transcription of the target genes.
TYK2-LOF is a rare molecular origin of PID, which was described
in 10 patients from eight unrelated families.37e40 The first case is a
Japanese boy, living in Tokyo metropolitan area with westernized
life style, suffering from mycobacterial and skin viral infections
associated with hyper IgE phenotype.37 Later, Dr. Casanova's group
identified five families with TYK2 deficiency. The patients live in
Turkey, Morocco, Iran and Argentina. The patients presented with
mycobacterial and viral disease without hyper IgE phenotype.37 In
addition, another TYK2-LOF patient with features of hyper IgE
phenotype was reported in 2016.39 Common features of all the
patients are intracellular bacterial infections including Mycobac-
terium and Salmonella and various viral infections including herpes
simplex virus infection and molluscum contagiosum. Only two
patients, however, present hyper-IgE phenotype. In these two pa-
tients, the mutations are C70HfsX21 and P216RfsX14, it is
unlikely that the phenotypic difference is caused by the
genotypeephenotype relationship (Fig. 5). Environmental factors
might be associatedwith this phenotypic difference. Because TYK2-
LOF patients have defects in Th1 cell differentiation due to theFig. 5. Structure and mutations of TYK2. TYK2 is a non-receptor tyrosine kinase,
consisting of FERM, SH2, pseudokinase, and kinase domain. The locations of homo-
zygous LOF mutations are shown in red.impaired IL-12 signaling, Th2 biased differentiation might be more
easily obtained under certain circumstances. Genetic modifier
genes are also a possibility, because of the difference in the IL-6
signaling between the two TYK2-LOF patients with atopic mani-
festations, but so far we were not successful to pin point a genetic
modifier gene.
SPINK5-LOF
Comel-Netherton syndrome is an AR PID characterized by ich-
thyosiform erythroderma, trichorrhexis invaginata (bamboo hair),
and atopic manifestations. In 1949, Comel reported this disorder is
characterized by erythroderma associated with itchymosis.41 In
1958, Netherton reported that this disorder is associated with
characteristic bamboo hair.42 The molecular cause of this disorder is
LOF mutation of Serine protease inhibitor, Kazal type 5 (SPINK5),
mainly expressed in skin and mucosa.43 The identification of this
disorder revealed that the serine protein inhibitor plays a critical
role in the pathogenesis of PID and formation of normal hair shape.
Due to SPINK5-LOF mutations, serine protease activity increases
in the stratum corneum, resulting in increased exfoliation and
epidermal barrier dysfunction and immune disorders. Immune
abnormalities were originally considered to be secondary to the
excessive invasion of allergens due to abnormal epidermal barrier
function. But more recently, intrinsic immune abnormalities in
SPINK5 deficiency was reported.44 Immediately after birth, ich-
thyosis begins on the face and spreads throughout the body.
Bamboo hair presents with invaginated hair fissures, twisted hairs,
or nodular hair splits. In severe cases, SPINK5-LOF is life-
threatening, and even in mild cases, it presents with systemic
features including failure to thrive., aminoaciduria, susceptibility to
infection, defect in thermoregulation, and dehydration.
Atopic manifestations include food allergies, cedar pollinosis,
bronchial asthma, and atopic dermatitis. Laboratory examination
shows an increase in total IgE and an increase in various allergen-
specific IgE, and eosinophilia. Markedly high trypsin-like enzyme
activity in the stratum corneum, attenuation of SPINK5 protein
expression by immunostaining in the epidermis. Mouse models
lacking the Spink5 also have the similar clinical features as humans,
such as abnormal epidermal detachment and abnormal hair shape.45
TGFBR1/2-GOF
TGF-b plays an important role in normal development and ho-
meostasis. TGFBR1 and 2 are serine/threonine and tyrosine kinases.
Canonical TGF-b signaling ignites when TGFB1/2/3 binds to
TGFBR2, which recruits and phosphorylates TGFBR1. Then, acti-
vated TGFBR1 phosphorylates mothers against decapentaplegic
homolog 2 (SMAD2) and SMAD3, which further recruit SMAD4 and
translocate to the nucleus where it regulates the transcription of
TGF-b target genes.46 Loeys-Dietz syndrome (LDS), caused by the
GOF mutations of TGFBR1/2, is characterized by the triad of arterial
tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft
palate.47 Most of the mutations are heterozygous missense muta-
tions, located in cytoplasmic protein kinase region of the receptors
(Fig. 6). The patients have craniofacial involvement consisting of
cleft palate, craniosynostosis, and hypertelorism. Most of these
non-immunological manifestations overlap with those of STAT3-
DN HIES.
Atopic diseases of LDS include asthma, food allergy, atopic
dermatitis, allergic rhinitis, and eosinophilic gastrointestinal dis-
ease, therefore, atopic manifestations are not limited to the skin.
In immune organs, TGFBR1/2-GOF HIES patients show excessive
nuclear accumulation of phosphorylated Smad2 in the thymus
compared to age-matched unaffected individuals. Additionally,
Fig. 6. Structure and mutations of TGRBR1 and TGFBR2. TGRBR1 and TGFBR2 are
single-pass transmembrane protein, having protein kinase domain in the cytoplasmic
region. The locations of heterozygous missense GOF mutations are shown in red.
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demonstrated increased expression of pSmad2/3 after stimulation
with TGFb1 when compared to unaffected individuals. These data
are consistent with the idea that the causative variants function as
GOF. TGFBR1/2-GOF patients exhibited elevated serum IgE levels,
eosinophil number, and Th2 cytokines in the blood. Interestingly,Fig. 7. Signal transduction pathway and structure and mutations of CARD11. CBM comple
transmit a signal to mTOR and NF-kB pathway. N-terminal CARD domain of CARD11 and B
form a CBM complex. Most of the disease-causing mutations are missense DN mutations, sTh2 cytokine-producing CD4þ T cells accumulate in cultures of
naïve CD4þ T cells from TGFBR1/2-GOF patients after stimulation
with TGF-b, suggesting that TGFBR1/2-GOF mutations support
Th2 skewing in a CD4þ T cell intrinsic manner. Future studies are
necessary to elucidate the molecular mechanism of TGFBR1/2-
GOF mutations can induce Th2 biased iTreg differentiation in
the patients.CARD11-DN
Caspase recruitment domain-containing protein 11 (CARD11
also known as CARMA1) is a component of the trimer complex of
CARD11-B-cell lymphoma/leukemia 10 (BCL10)-mucosa-associated
lymphoid tissue lymphoma translocation protein 1 (MALT1) (CBM
complex), which is involved in NF-kB and mammalian target of
rapamycin (mTOR) activation via T cell receptor (TCR) and B cell
receptor (BCR) signaling. GOF mutations of the CARD11 gene re-
ported to cause a lymphoproliferative disease known as BENTA (B
cell expansionwith NF-kB and Tcell anergy),48e50 and bi-allelic loss
of functionmutations causes a Severe combined immunodeficiency
(SCID)-like phenotype.51,52 In 2017,53 DN mutations in the CARD11
gene were identified in patients with severe atopic dermatitis and
other allergic conditions with or without infections.54 More
recently, the evaluation of larger cohort revealed that a broader
phenotypic variations was associated with CARD11-DN, including
cutaneous viral infections, respiratory tract infections, neutropenia,
hypogammaglobulinemia, and lymphoma.55 Laboratory investiga-
tion shows elevated serum IgE levels, eosinophilia, and low mem-
ory B lymphocytes. Serum IgG is variable, with some patients
having hypogammaglobulinemia. Because most of the patients
present with poor mitogen-stimulated T cell proliferation,55 in the
future, this disorder may be classified into CID category.
Most of the mutations of CARD11-DN are located in the N-ter-
minal CARD domain and coiled coil (CC) domain (Fig. 7). Missense
mutations in the N-terminal CARD domain are likely to disrupt
interactions with BCL10, resulting in the defect in nuclear factor-
kappa B (NF-kB) signaling. The coiled coil domain is also a hot-
spot for the mutations, the mutations in which is likely to disruptx is located in the downstream signal transduction pathway of TCR and BCR, which
CL10, coiled-coil domain of CARD11 and CASP domain of MALT1 interact each other to
hown in red, are located in the CARD, coiled-coil, and GUK domain.
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tions found in patients with BENTA, these mutations did not drive
constitutive NF-kB activation in the absence of antigen receptor
stimulation.
Atopic disease was the prominent feature in most patients with
CARD11-DN (89%), most frequently presenting with atopic
dermatitis (73%) but also including asthma (55%), food allergies
(32%), and eosinophilic esophagitis (7%). However, atopy was mild
or absent in at least 10% of the patients, with no discernible dif-
ferences in CARD11 signaling function. Furthermore, unrelated
patients with the same mutation and even family members
harboring identical mutations demonstrated differences in the
variety and severity of manifestations. These observation suggests
that environmental factors or genetic modifiers might be associ-
ated with the development of atopic disorders in CARD11-DN HIES.
Insufficient humoral responses, such as low IgM levels, appear to be
a common in impaired CARD11 signaling with or without increased
IgE levels. A number of families presented with more severe hu-
moral defects resembling common variable immunodeficiency
(CVID), which may be contributed by intrinsic defects in B-cell and
extrinsic defects in T cells.
Cutaneous viral infections, including molluscum contagiosum
and herpes simplex virus 1 infections, were also common to the
CARD11-DN HIES patients. Impaired CD8þ T-cell immuno-
surveillance could be a causal factor. Interestingly, patients with
BENTA carrying CARD11-GOF mutations often present with mol-
luscum contagiosum and Epstein-Bar virus infections. Both
CARD11-GOF and CARD-DN mutations resulted in similar skin viral
infections.
Other PIDs with high serum IgE levels
Several other PIDsmainly from the CID category are characterized
by high serum IgE levels and susceptibility to infections. The PIDs,
including WiskotteAldrich syndrome, DOCK8 deficiency, PGM3
deficiency, and Omenn Syndrome, are all characterized by decreases
in T-cell numbers and an impairment in T-cell proliferation. Causa-
tive genes of Omenn syndrome include Recombination-activating
gene (RAG)1, RAG2, IL2RG, IL7R, DNA ligase 4 (LIG4), DNA cross-link
repair 1C (DCLRE1C), RNA component of mitochondrial RNA process-
ing endoribonuclease (RMRP), adenosine deaminase (ADA), protein ki-
nase, DNA-activated, catalytic (PRKDC). The high serum IgE levelsmay
result fromweak TCR signaling insufficient to induce Treg cells, and/
or an imbalance in the Th1/Th2 differentiation. Immune-
dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)
syndrome is caused by the LOF mutations in the FOXP3 gene, is also
one of the PID with high serum IgE levels. This indicates that the lack
of regulatory Tcells alone is sufficient to induce high serum IgE levels
in the patient. It is necessary to exclude these disorders/genes to
diagnose HIES.
Concluding remarks
Major progress has been made in our understanding of mono-
genic diseases that cause hyper IgE phenotype associated with
susceptibility to infection. The definition of HIES can be divided at
least into three categories: (1) the definition that include only pa-
tients who present with clinical symptoms identical to the original
STAT3-DNHIES, (2) the definition that includes all the patients with
atopic dermatitis, high serum IgE levels, and susceptibility to in-
fections, and (3) the definition that exclude the CID patients with
defects in T cell proliferation, from patients with the definition (2).
In this article, the definition 3 was adopted because the molecular
pathogenesis of HIES is more relevant to the mechanism of com-
mon atopic disorders by applying this definition. Regardless ofwhich definition is adopted, elucidation of the etiology and path-
ophysiology of HIES is helpful for elucidation of the human immune
system,mechanism of atopic diseases, and the development of new
therapeutic approaches.
At present, distinguishing HIES patients from common atopic
disorders, especially early in life, is not an easy task. Consultation
with the PID specialists is recommended, however, even for PID
specialists, it is difficult to distinguish the HIES from common
atopic disorders. In this setting, a detailed family history and clin-
ical course associated with specific laboratory tests for HIES is
essential. From a clinical standpoint, early exclusion of CID is
especially important, because the number of CID patients with high
serum IgE levels is relatively large and earlier and curative treat-
ment might be crucial for the prognosis of the patients. Eventually,
HIES can be distinguished from common atopic disorders by
observing the clinical course, usually the development and recur-
rence of unusual infectious episodes or the association of non-
immunological manifestations. If there is enough evidence to
indicate that the patients are different from common atopic dis-
eases, genetic testing panels for the causative genes of HIES is the
method of definitive diagnosis.
There are challenges in elucidating the pathogenesis and
pathophysiology of HIES. Regarding IL-6R-LOF HIES, the discussion
was based on the clinical and laboratory findings of only two pa-
tients. At present, it is technically difficult to completely rule out
the possibility that modifier genes may affect the phenotype of
these HIES patients. Especially, if the number of the patients is
limited and there are some discrepancies in the phenotype of the
patients, such as severe and mild atopy. Strong regional bias of the
HIES patients is also a concern for the interpretation of patho-
genesis of HIES, because it is well known that environmental fac-
tors are deeply involved in the pathogenesis of atopic disorders.
Although PID research has witnessed many examples of the same
genetic abnormality has different phenotypes between humans
and mice, but it is still necessary to make good use of mouse
models for the understanding of PID pathogenesis. More new ge-
netic causes of HIES are likely to be identified in the near future.
Many new patients with HIES are likely to be identified by
worldwide application of recently developed genetic technologies.
These advances are certain to help HIES research to elucidate the
understanding of human immunology and the development of
treatments for atopic disorders.
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